<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907162</url>
  </required_header>
  <id_info>
    <org_study_id>PainNMD Version 1</org_study_id>
    <nct_id>NCT04907162</nct_id>
  </id_info>
  <brief_title>Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders</brief_title>
  <official_title>Nociceptive Pain in Neuromuscular Disorders - Low Interventional Pilot Study to Assess Musculoskeletal Pain in Neuromuscular Disorders (NMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to characterize the prevalence, severity and quality of musculoskeletal&#xD;
      nociceptive pain in adult patients with neuromuscular disorders (NMD). The secondary&#xD;
      objectives are to evaluate whether severity and distribution of muscle pain is associated&#xD;
      with muscle function, and to assess whether muscle pain is associated with alterations of&#xD;
      muscle elasticity and muscle stiffness. Results of patients with neuromuscular disorders will&#xD;
      be compared to age- and gender-matched healthy volunteers. Approx. 70 patients with&#xD;
      neuromuscular disorders and 20 healthy volunteers will be enrolled, including patients with&#xD;
      the following neuromuscular disorders: histologically confirmed inclusion body myositis&#xD;
      (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal&#xD;
      muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy&#xD;
      (FSHD), genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). The duration of&#xD;
      patient recruitment will be around 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The explorative, cross-sectional low-interventional pilot study evaluates the prevalence,&#xD;
      severity and quality of musculoskeletal nociceptive pain in participants with defined&#xD;
      neuromuscular disorders (NMD). Adult participants with the following neuromuscular disorders&#xD;
      will be included: histologically confirmed inclusion body myositis (IBM), genetically&#xD;
      confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type&#xD;
      3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) and genetically&#xD;
      confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). 20 healthy participants will be&#xD;
      enrolled as a control group. The Beck depression inventory fast screen (BDI-FS) will be used&#xD;
      as a screening. If there is a possibility of major depression (with a BDI ≥4), patients will&#xD;
      be excluded from the study. So only patients with BDI-FS score ≤3 at screening will be&#xD;
      enrolled. Patients will be asked to complete the following validated disease-related and&#xD;
      quality-of-life questionnaires: German Pain Inventory (module A and abbreviated module S and&#xD;
      L and V), Brief Pain Inventory (BPI) and Fatigue Severity and Disability Scale (FSS).&#xD;
      Demographic and disease related data will be obtained. A neuromuscular examination will be&#xD;
      conducted. A clinical evaluation of muscle strength using the MRC-Scale (Medical Research&#xD;
      Council-Scale) will be performed on both sides deltoid muscles, biceps brachii muscles,&#xD;
      triceps brachii muscles, hip flexors, hip extensors, quadriceps femoris muscles, foot&#xD;
      extensor and foot flexor muscles as well as axial muscles and neck flexors and extensors. The&#xD;
      Quick Motor Function Test (QMFT) with 16 items will be performed to assess muscle and&#xD;
      movement functions of the participants. To ensure a high level of objective measurement,&#xD;
      muscle strength will also be assessed by using handheld dynamometry. The following muscle&#xD;
      groups will be tested: arm abduction, elbow flexion, elbow extension, hip flexion, hip&#xD;
      extension, knee extension, knee flexion, foot extension, foot flexion. A six-minute-walk test&#xD;
      (6MWT) will be performed once. Additionally, first signs of muscle pain or muscle cramps will&#xD;
      be recorded (including the quality and intensity of pain). The Borg scale to rate dyspnea&#xD;
      will be administered before starting the 6MWT and after completing the 6MWT. For diagnosis of&#xD;
      myofascial pain, a Pressure Pain Threshold test by using a pressure algometer is included for&#xD;
      the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the&#xD;
      tibialis anterior muscles until the patient feels any sensation of pain. Measurement of&#xD;
      muscle stiffness, muscle tone, relaxation periods and viscoelasticity of selected muscles&#xD;
      will be assessed by a myotonometer. Data collected in this study will be reported using&#xD;
      summary tables, figures, and patient data listings. Differences between the patients and the&#xD;
      healthy volunteers will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of musculoskeletal pain in defined neuromuscular diseases</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>The primary aim is to characterize the prevalence of musculoskeletal pain in adult patients with neuromuscular disorders (NMD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between musculoskeletal pain and muscle function, assessed by Medical research council (MRC) grading (0-5)</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Assessed by Medical research council (MRC) grading (0-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between musculoskeletal pain and muscle function, assessed by quick motor function test (QMFT)</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Assessed by quick motor function test (QMFT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between musculoskeletal pain and muscle function, assessed by Pressure Pain Threshold (PPT)</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Assessed by Pressure Pain Threshold (PPT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between musculoskeletal pain and muscle function, assessed by a Myotonometer</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Assessed by a Myotonometer (incl. relaxation time, stiffness, muscle tone, relaxation periods and viscoelasticity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Questionnaire: Beck depression inventory fast screen</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Association between Depression and musculoskeletal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Questionnaire: Brief Pain Inventory</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Association between Depression and musculoskeletal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Questionnaire: Fatigue Severity Scale (FSS)</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Association between Depression and musculoskeletal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of musculoskeletal pain (quality and severity) assessed by the German Pain Questionnaire</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Characterization of quality and severity of musculoskeletal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of musculoskeletal pain (quality and severity) assessed by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Only at baseline visit</time_frame>
    <description>Characterization (quality and severity) of musculoskeletal pain</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pompe Disease (Late-onset)</condition>
  <condition>Myotonic Dystrophy Type 1 (DM1)</condition>
  <condition>Myotonic Dystrophy Type 2</condition>
  <condition>Spinal Muscular Atrophy Type 3</condition>
  <condition>Inclusion Body Myositis, Sporadic</condition>
  <condition>Facioscapulohumeral Muscular Dystrophy 1</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <description>The patient has one of the following neuromuscular diagnoses:&#xD;
histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or&#xD;
genetically confirmed late-onset Pompe disease (LOPD), or&#xD;
genetically confirmed spinal muscular atrophy type 3 (SMA3), or&#xD;
genetically confirmed myotonic dystrophy type 1, or&#xD;
genetically confirmed myotonic dystrophy type 2, or&#xD;
genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>no known neuromuscular disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Beck depression inventory fast screen</intervention_name>
    <description>Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>BDI-FS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>German Pain Inventory</intervention_name>
    <description>German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>Deutscher Schmerzfragebogen (DSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brief Pain Inventory</intervention_name>
    <description>Validated questionnaire for pain.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>BPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fatigue Severity and Disability Scale (FSS)</intervention_name>
    <description>Validated questionnaire for perceived fatigue</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>FSS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quick Motor Function Test</intervention_name>
    <description>An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>QMFT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Handheld Dynamometry (HHD)</intervention_name>
    <description>To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>HHD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Six-minute walk test (6MWT)</intervention_name>
    <description>It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>6MWT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pressure pain threshold</intervention_name>
    <description>For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of &quot;burning&quot;, &quot;stinging&quot;, &quot;drilling&quot; or &quot;aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>PPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Myotonometer Assessment</intervention_name>
    <description>Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vital signs</intervention_name>
    <description>Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
    <other_name>Vital parameters (VP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Borg Scale</intervention_name>
    <description>the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Neuromuscular disease (NMD) Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 70 patients with defined NMD (see inclusion criteria) will be enrolled. For a&#xD;
        control group, 20 healthy volunteers will be enrolled. All patients must be ≥ 18 years of&#xD;
        age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  The participant is willing and able to provide signed informed consent.&#xD;
&#xD;
          -  The participant is able and willing to perform study-related assessments.&#xD;
&#xD;
          -  The participant is ≥18 years of age&#xD;
&#xD;
          -  The participant has one of the following diagnoses:&#xD;
&#xD;
               -  histologically confirmed inclusion body myositis (IBM), or&#xD;
&#xD;
               -  genetically confirmed late-onset Pompe disease (LOPD), or&#xD;
&#xD;
               -  genetically confirmed spinal muscular atrophy type 3 (SMA3), or&#xD;
&#xD;
               -  genetically confirmed myotonic dystrophy type 1, or&#xD;
&#xD;
               -  genetically confirmed myotonic dystrophy type 2, or&#xD;
&#xD;
               -  genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The participant is participating in another clinical study or using an investigational&#xD;
             treatment.&#xD;
&#xD;
          -  The participant, in the opinion of the Investigator, is unable to adhere to the&#xD;
             requirements of the study.&#xD;
&#xD;
          -  The participant has currently a severe depression, assessed by the Beck depression&#xD;
             inventory fast screen (BDI-FS) with a score ≥ 4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Wenninger, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Wenninger, PD Dr. med.</last_name>
    <phone>49089440057470</phone>
    <email>stephan.wenninger@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Sagerer</last_name>
    <phone>49089440057470</phone>
    <email>s-esagerer@helios.med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Friedrich-Baur-Institute</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Wenninger, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Benedikt Schoser</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>nociceptive pain</keyword>
  <keyword>musculoskeletal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

